OakChart

Addex Therapeutics Ltd ADR

ADXNHealthcare·Biotechnology·Switzerland·Nano·NASD·Nov 11 • 11:06 AM ET

2.84-0.05 (-1.57%)
2026-11-11 21:10 CET
Market cap
3.07 USD m
Revenue, TTM
0.10 USD m
Net income, TTM
-8.66 USD m
Free cash flow, TTM
-3.03 USD m
EPS diluted, TTM
-8.81
P/E
-
Compare

Price

ADXN against its 20, 50 and 200-day averages
2050200earnings
4.006.008.003.6M7.3MVolumeApr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ADXNclose 2.8520-day 2.9450-day 3.15200-day 5.842.8552w low

76.2% under the 52-week high of 11.97 on 17 Oct 2025. 52-week low 2.56 on 28 Sep 2026. Last 15 sessions, 19.0% high to low

the line is the 50-bar volume average

Profile

ADXN
52-week range, 4% of the way up
2.5610.43

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Employees3
IPOJan 29, 2020
Beta1.58
ATR, 14d0.20
Rel volume0.00
Short float0.56%
Insider own0.03%
Inst own0.02%

Snapshot

6 groups

Valuation

Index-
Market Cap3.02M
Enterprise Value2.17M
Income-8.66M
Sales0.10M
Book/sh2.22
Cash/sh0.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPOJan 29, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S30.15
P/B1.28
P/C3.17
P/FCF-
EV/EBITDA-
EV/Sales21.65
Quick Ratio0.76
Current Ratio0.76
Debt/Eq0.04
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-8.81
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y46.11% 31.85%
Sales past 3/5Y-48.38% -44.27%
EPS Y/Y TTM-3.77%
Sales Y/Y TTM-45.76%
EPS Q/Q18.74%
Sales Q/Q-71.39%
EarningsSep 28 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own0.03%
Insider Trans0.00%
Inst Own0.02%
Inst Trans-12.03%
ROA-115.52%
ROE-151.69%
ROIC-362.44%
Gross Margin52.26%
Oper. Margin-3142.13%
Profit Margin-8312.79%
SMA20-3.25%
SMA50-9.64%
SMA200-51.27%
Trades-

Technical

Shs Outstand1.06M
Shs Float1.06M
Short Float0.56%
Short Ratio0.04
Short Interest0.01M
52W High10.43 -72.73%
52W Low2.56 11.12%
Volatility7.08% 6.27%
ATR (14)0.20
RSI (14)43.16
Beta1.58
Rel Volume0.00
Avg Volume151.83K
Volume203

Performance

Perf Week-6.52%
Perf Month-5.49%
Perf Quarter-52.19%
Perf Half Y-58.59%
Perf YTD-63.15%
Perf Year-67.71%
Perf 3Y-49.39%
Perf 5Y-98.16%
Perf 10Y-
Recom4.50
Target Price22.87
Prev Close2.89
Price2.84
Change %-1.57%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jul 31, 2024UpgradeHH.C. WainwrightNeutral → Buy$30+954.6%

Peers

Mkt cap
TickerCompanyMkt cap
NEUPNeuphoria Therapeutics Inc14.72M
VTGNVistagen Therapeutics Inc8.32M
RAPPRapport Therapeutics Inc1.57B
NERVMinerva Neurosciences Inc122.59M
ACOGAlpha Cognition Inc190.45M
ANVSAnnovis Bio Inc36.00M
JUNSJupiter Neurosciences Inc2.86M
PRAXPraxis Precision Medicines Inc9.73B
RLMDRelmada Therapeutics Inc475.21M
CRVOCervoMed Inc26.86M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-28-1.442--1.4420.01--
2026Q12026-06-25-1.482--2.2110.01--
2025Q32025-12-04-1.498--2.0990.06--
2025Q22025-09-30-3.016--2.6590.05--
2024Q32024-11-22-2.685-1.420-2.1550.070.121
2024Q22024-09-3011.381-1.42410.1710.140.241
2024Q12024-06-06-1.345--4.3440.26--
2023Q32023-11-29-4.115-0.662-4.5980.380.661
2023Q22023-08-10-109.87--4.9450.72--
2023Q12023-05-11-5.368--5.0970.56--
2022Q42023-03-30-27.596--7.6120.66-1
2022Q32022-11-1111.418-1.856-10.6710.440.231
2022Q22022-08-18-23.890-2.706-23.9950.190.531
2022Q12022-05-05-18.272-10.326-19.9620.250.511
2021Q42022-04-12-16.780--16.6080.43-1
2021Q32021-11-04-14.460-17.054-13.7800.830.411

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY--245.57-0.160.27
2014FY---0.73-
2019FY-70.896-51.655-67.5322.953.59
2020FY-62.233-72.478-61.6134.193.22
2021FY-56.444-56.523-59.0563.333.76
2022FY-60.450-56.206-57.8501.581.23
2023FY-16.717-18.543-18.9701.801.21
2024FY-10.599-8.72010.0080.481.08
2025FY--10.465-9.054--
2026FY--5.980---
2027FY--4.080--0.00
2028FY-0.000--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q4S2025-01-081000.240.240.24
2025Q4S2025-01-071000.240.240.24
2025Q4S2025-01-061000.240.240.24
2025Q4S2025-01-051000.240.240.24
2025Q4S2025-01-041000.240.240.24
2025Q4S2025-01-031000.240.240.24
2025Q4S2025-01-021000.240.240.24
2025Q4S2025-01-011000.240.240.24
2025Q4S2024-12-311000.240.240.24
2025Q4S2024-12-301000.240.240.24
2025Q4S2024-12-291000.240.240.24
2025Q4S2024-12-281000.240.240.24
2025Q4S2024-12-271000.240.240.24
2025Q4S2024-12-261000.240.240.24

Estimate history

EPS, annual-30.904-8.658-67.532-61.613-59.056-57.85-18.975.734-9.054-8.8103
Period201720182019202020212022202320242025TTM
EPS, quarterly10.171-2.155-1.677-2-2.659-2.099-2.339-2.211-2.161
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.5086.8492.8513.8733.211.5131.80.4660.2080.1
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1270.0670.0020.0790.0440.0620.020.010.013
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1120.220.2220.2260.3160.4970.7940.820.9831.062
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.8190.8190.820.820.9270.9710.9830.9941.062
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.100.210.471.801.513.213.872.856.85
Cost of Goods Sold Incl. D&A0.050.010.30------
Gross Profit0.050.200.17------
Selling, General and Administrative Excl. Other3.333.593.303.9622.6620.0316.7717.218.30
Research and Development0.450.810.681.0915.1313.7510.7312.275.02
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-3.27-3.39-3.13-2.50-21.49-17.20-13.30-14.70-1.46
Interest Expense0.000.000.000.000.050.070.070.130.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-3.28-3.41-5.57-2.78-21.78-16.79-13.70-14.87-1.68
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-8.66-8.24-5.57-2.78-21.78-16.79-13.70-14.87-1.68
Net Income From Continuing Operations-8.66-8.24-5.57-2.78-21.78-16.79-13.70-14.87-1.68
Net Income-8.66-8.108.01-11.75-21.78-16.79-13.70-14.87-1.68
EPS (Recurring)-8.48-9.055.73-18.97-57.85-59.06-61.61-67.53-8.66
EPS (Basic, Before Extraordinaries)-8.81-9.059.80-18.97-57.85-59.06-61.61-67.53-8.66
EPS (Diluted)-8.81-9.055.73-18.97-57.85-59.06-61.61-67.53-8.66
EBITDA-3.22-3.38-2.83-2.16-21.15-16.82-12.90-14.36-1.45
Non-Operating Income (Expense)0.00-0.02-2.44-0.28-0.250.48-0.32-0.05-0.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.010.020.033.181.040.961.320.56
Price To Earnings Ratio--1.03------
Price To Sales Ratio55.8933.1921.002.083.1411.1415.39--
Gross Margin52.2695.1036.56------
Operating Margin-3,142.13-1,628.25-671.94-138.70-1,420.12-535.75-343.55-515.38-21.25
Net Margin-8,312.79-3,892.311,720.75-652.75-1,439.78-523.07-353.76-521.61-24.54
Shares Outstanding1.060.980.820.790.500.320.230.220.22
Market Capitalization3.073.075.745.885.5839.7360.5763.76-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.010.010.020.060.040.080.000.07
Cost of Goods Sold Incl. D&A0.030.010.000.000.00-0.030.06
Gross Profit-0.02-0.000.020.060.04--0.030.01
Selling, General and Administrative Excl. Other0.800.610.990.930.930.750.480.72
Research and Development0.050.050.070.290.280.170.070.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.82-0.61-0.98-0.87-0.89-0.67-0.51-0.72
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-0.81-0.62-0.98-0.87-0.88-0.70-1.36-1.76
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.21-2.18-2.29-1.97-2.37-1.64-1.36-1.76
Net Income From Continuing Operations-2.21-2.18-2.29-1.97-2.37-1.64-1.36-1.76
Net Income-2.21-2.18-2.30-1.97-2.23-1.64-1.37-1.77
EPS (Recurring)-2.16-2.21-2.34-2.10-2.66-2.00-1.68-2.16
EPS (Basic, Before Extraordinaries)-2.16-2.21-2.34-2.10-2.66-2.00-1.68-2.15
EPS (Diluted)-2.16-2.21-2.34-2.10-2.66-2.00-1.68-2.15
EBITDA-0.78-0.60-0.97-0.87-0.88-0.67-0.48-0.66
Non-Operating Income (Expense)0.00-0.00-0.00-0.000.01-0.02-0.85-1.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.000.000.000.000.000.000.00
Price To Earnings Ratio----0.811.081.032.23
Price To Sales Ratio55.8945.8237.0447.5441.0421.8312.3311.94
Gross Margin-153.58-27.6886.6295.7394.18--1,478.188.18
Operating Margin-6,487.38-6,238.86-4,922.63-1,403.58-2,014.84-853.23-29,545.83-1,066.38
Net Margin-17,538.32-22,256.58-11,604.31-3,179.90-5,061.63-2,072.85-79,942.54-2,622.20
Shares Outstanding1.060.990.980.970.930.820.820.82
Market Capitalization3.077.919.717.757.716.015.748.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2.073.694.597.5222.4821.1532.5742.272.65
Short Term Receivables0.030.020.180.650.360.080.120.280.31
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.020.200.260.291.220.560.760.210.17
Total Current Assets2.113.905.038.4624.0621.7933.4542.763.13
Net Property, Plant & Equipment0.040.050.420.430.590.720.590.010.00
Total Investments and Advances5.867.820.000.000.000.000.000.060.01
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.010.010.060.060.060.250.070.000.00
Total Assets8.0311.785.518.9524.7222.7634.1142.823.14
Short Term Debt Incl. Current Port. of LT Debt0.010.010.330.310.320.350.390.000.00
Accounts Payable0.760.281.171.381.961.112.291.170.39
Other Current Liabilities0.740.601.941.862.262.633.191.201.12
Total Current Liabilities1.510.893.443.554.544.105.872.371.52
Long Term Debt0.030.040.080.090.210.290.180.000.00
Provision for Risks Charges0.470.180.530.001.411.911.530.650.25
Other Liabilities0.000.000.110.000.000.000.170.000.00
Total Liabilities2.021.104.153.646.166.307.753.021.77
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6.0110.671.365.3118.5616.4526.3639.811.38
Total Shareholders Equity6.0110.671.365.3118.5616.4526.3639.811.38
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6.0110.671.365.3118.5616.4526.3639.811.38
Total Liabilities & Stockholders Equity8.0311.785.518.9524.7222.7634.1142.823.14
Book Value Per Share6.1213.021.7110.6758.7872.81118.89180.9012.32
Tangible Book Value Per Share6.1213.021.7110.6758.7872.81118.89180.9012.32
Full-Time Employees322324282723178
Price to Book Ratio1.300.440.950.692.143.683.72--
Return on Assets-83.21-64.48-38.47-129.39-70.73-48.18-38.67-7.31-138.89
Return on Equity-98.78-92.67-83.46-182.51-95.90-64.00-44.96-8.16-418.51
Return on Invested Capital-134.0474.81-813.72-403.33-89.43-81.80-56.04-4.22-241.92
Quick Ratio1.404.411.462.385.305.325.7018.062.07
Current Ratio1.404.411.462.385.305.325.7018.062.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.73-8.108.01-11.75-21.78-16.79-13.70-14.87-1.68
Depreciation0.050.010.300.340.340.380.400.340.00
Other Funds (Non Cash)5.454.81-13.012.324.050.921.921.942.36
Funds from Operations-3.22-3.28-4.71-9.08-17.40-15.49-11.38-12.600.68
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.190.66-1.390.240.17-0.65-1.642.971.08
Cash from Operating Activities-3.03-2.62-6.10-8.85-17.23-16.15-13.01-9.631.76
Capital Expenditures0.000.00-0.00-0.01-0.00-0.03-0.06-0.03-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.35-0.340.000.000.000.000.00-0.01-0.05
Purchase of Investments-0.35-0.340.000.000.000.000.00-0.01-0.05
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.30-0.61-0.540.000.000.000.000.00-0.01
Other Sources0.070.145.810.000.000.000.000.000.00
Cash from Investing Activities0.03-0.825.27-0.010.00-0.03-0.06-0.04-0.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.081.440.206.123.5718.340.48-0.0638.23
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.081.440.206.123.5718.340.48-0.0638.23
Proceedsfrom Stock Options1.081.440.206.120.6018.340.48-0.0638.23
Issuance or Reduction of Debt, Net--0.000.000.000.00--0.320.00
Change in Long Term Debt--0.000.000.000.00--0.00
Issuance of Long Term Debt---0.000.000.00--0.00
Reduction of Long Term Debt--0.000.000.000.00--0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1.031.430.125.813.2718.000.09-0.3738.23
Exchange Rate Effect0.00-0.040.11-0.40-0.210.13-0.69-0.150.01
Net Change in Cash-1.97-2.05-0.59-3.44-14.161.96-13.68-10.2039.94
Free Cash Flow-3.03-2.62-6.10-8.85-17.23-16.18-13.08-9.661.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.951.162.072.752.893.19
Short Term Receivables0.040.040.030.060.050.04
Inventories0.000.000.000.000.000.00
Other Current Assets0.290.270.020.150.390.37
Total Current Assets1.281.482.112.963.333.61
Net Property, Plant & Equipment0.090.130.040.050.050.05
Total Investments and Advances2.874.255.866.197.297.05
Intangible Assets0.000.000.000.000.000.00
Other Assets0.070.070.010.010.010.01
Total Assets4.315.928.039.2010.6810.71
Short Term Debt Incl. Current Port. of LT Debt0.070.100.010.010.010.01
Accounts Payable0.960.790.760.510.800.32
Other Current Liabilities0.660.640.740.960.630.86
Total Current Liabilities1.691.521.511.481.451.19
Long Term Debt0.030.030.030.040.040.04
Provision for Risks Charges0.230.280.470.210.140.11
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.951.832.021.721.621.34
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2.364.096.017.489.059.37
Total Shareholders Equity2.364.096.017.489.059.37
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2.364.096.017.489.059.37
Total Liabilities & Stockholders Equity4.315.928.039.2010.6810.71
Book Value Per Share2.224.116.127.709.7611.43
Tangible Book Value Per Share2.224.116.127.709.7611.43
Full-Time Employees--3---
Price to Book Ratio1.300.821.000.970.820.46
Return on Assets-115.52-106.04-83.55-62.09-55.00-88.36
Return on Equity-151.69-131.07-99.18-71.25-61.63-162.42
Return on Invested Capital-92.37-53.04-38.03-26.22-24.49-17.42
Quick Ratio0.760.971.402.012.303.02
Current Ratio0.760.971.402.012.303.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.21-2.18-2.28-2.05-2.18-1.64
Depreciation0.030.010.000.000.000.00
Other Funds (Non Cash)1.371.601.311.171.360.99
Funds from Operations-0.82-0.58-0.96-0.87-0.82-0.65
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.22-0.400.190.180.31-0.02
Cash from Operating Activities-0.60-0.98-0.77-0.69-0.51-0.67
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00-0.00-0.340.000.00
Purchase of Investments0.000.00-0.00-0.340.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-0.010.31-0.920.00
Other Sources0.000.00-0.000.070.070.00
Cash from Investing Activities0.000.00-0.010.04-0.850.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.410.090.110.470.750.11
Repurchase of Common Pref Stock-0.000.000.000.000.000.00
Sale of Common Pref Stock0.410.090.110.470.750.11
Proceedsfrom Stock Options0.410.090.110.470.750.11
Issuance or Reduction of Debt, Net-0.00-0.000.000.00
Change in Long Term Debt-0.00-0.000.000.00
Issuance of Long Term Debt-0.00-0.000.000.00
Reduction of Long Term Debt-0.00-0.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.370.080.100.470.750.11
Exchange Rate Effect0.01-0.00-0.00-0.00-0.02-0.02
Net Change in Cash-0.21-0.90-0.68-0.19-0.62-0.57
Free Cash Flow-0.60-0.98-0.77-0.69-0.51-0.67

Revenue breakdown

Pharmaceutical Preparations2024: 459.00K 2025: 36.07K
Switzerland2024: 459.00K 2025: 36.07K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.56%0.0M1.1M159.41K
2026-10-150.53%0.0M1.1M174.30K
2026-09-300.17%0.0M1.1M187.39K
2026-09-150.03%0.0M1.0M187.30K
2026-08-310.42%0.0M1.0M180.25K
2026-08-140.72%0.0M1.0M3.57K
2026-07-310.42%0.0M1.0M3.57K
2026-07-150.09%0.0M1.0M4.28K
2026-06-300.15%0.0M1.0M4.77K
2026-06-150.14%0.0M1.0M4.74K
2026-05-290.51%0.0M1.0M4.16K
2026-05-150.51%0.0M1.0M4.38K
2026-04-300.51%0.0M1.0M4.85K
2026-04-150.58%0.0M1.3M4.48K
2026-03-310.54%0.0M1.3M5.92K
2026-03-130.87%0.0M1.3M5.32K
2026-02-270.95%0.0M1.3M6.88K
2026-02-130.40%0.0M1.3M7.28K
2026-01-300.34%0.0M1.3M6.96K
2026-01-150.36%0.0M1.3M13.30K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-25SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-04SCHEDULE 13D/ASEC
2026-08-27SCHEDULE 13D/ASEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-07-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-08SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-05-1520-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-30NT 20-F2025-12-31SEC
2026-04-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-29SEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-23SEC
2026-04-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-21SEC
2026-03-253Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-253Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-253Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-253Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
UBS Group AG0.12%
SBI Securities Co., Ltd.0.01%

Funds

Fund% owned
-

OakChart. ADXN. Cached 15 minutes.

Some panels did not load: insider.